Gynäkologisches Krebszentrum Regensburg


Offene klinische Studien – Stand September 2016







Phase III

Patient with newly diagnosed
- Ovarian cancer, primary peritoneal cancer and/or fallopian-tube cancer,
- Histologically confirmed (based on local histopathological findings):
• high grade serous or
• high grade endometrioid or
• other epithelial non mucinous ovarian cancer in a patient with germline BRCA 1 or 2 deleterious mutation at an advanced stage: FIGO stage IIIB, IIIC, or IV of the 1988 FIGO classification.

Randomized, double-blind, Phase III Trial of olaparib vs. placebo in patients with advanced FIGO stage IIIB – IV high grade epithelial ovarian, fallopian tube, or peritoneal cancer treated with standard first-line treatment, combining platinumtaxane chemotherapy and bevacizumab concurrent with chemotherapy and in maintenance.

 C-Patrol NISPat. mit histologisch gesichertem Platin-sensitiven Rezidiv eines BRCA-mutierten high-grade serösen epithelialen Ovarial-Ca, Eileiter-Ca oder primären Peritoneal-Ca, die auf eine Platin-basierte Chemotherapie ansprechenA single arm, prospective Non- Interventional Study to collect Clinical and Patient reported outcome data in an Olaparib treated BRCAm+ PSR ovarian cancer population 

Kontakt Anfahrt Seite drucken© 2002-2019 Caritas-Krankenhaus St. Josef | Impressum | Datenschutz | Sitemap | Design & Programmmierung